FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

The Safety Profile of AUBAGIO (teriflunomide)‎ for MS treatment: VIDEO





















It’s important, Aaron Miller, MD Professor of Neurology and Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Hospital in New York said, to also look at the safety profile of the drug – these safety data in the TOPIC extension trial were very comparable to those that were seen in the pivotal phase 3 relapsing remitting trials.“These are generally very mild, and principally occur early in the course of treatment.”
A small percent experienced hair thinning that caused them to drop out of the trial. But, those who experienced this is the rest of the group typically saw virtually no reports of hair thinning 6-12 months after beginning the drug treatment.

A small percent had elevations of transaminases. Though usually mild, it’s important for people to remember that the US prescribing info recommends monthly liver function tests for the first 6 months.

The third side effect worth mentioning are generally mild GI symptoms that mostly consist of diarrhea. They are more common earlier on, but some physicians do see an occasional patient who continues to experience diarrhea as he or she continues on the drug therapy.

According to Miller, there was one other aspect of data reported in the poster about the effect on lymphocyte counts. Low lymphocyte counts are often a concern with some medications in multiple sclerosis; however, the mean lymphocyte counts stayed up in the normal range throughout treatment with teriflunomide and virtually no patients have a severe drop in lymphocyte counts.

“This appears to be a very safe and effective drug, and is a valuable part of our therapeutic armamentarium. I don’t think teriflunomide addresses all the unmet needs in MS, in fact, no drug meets all the unmet needs, but this is a very well tolerated oral agent.” Miller said.

Story Source: The above story is based on materials provided by MDMAG
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News